Acceptability of ENG-releasing subdermal implants among postpartum Brazilian young women during the COVID-19 pandemic.


Journal

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174

Informations de publication

Date de publication:
Jul 2021
Historique:
revised: 17 02 2021
received: 14 12 2020
accepted: 01 03 2021
pubmed: 4 3 2021
medline: 22 6 2021
entrez: 3 3 2021
Statut: ppublish

Résumé

To evaluate etonogestrel (ENG)-implant acceptance during the immediate postnatal period among adolescents and young women during the COVID-19 pandemic, and to compare variables according to choice and discuss possible implications of this measure during the pandemic period. A cross-sectional study was designed. All women aged up to 24 years, who delivered between April 25, 2020, and June 24, 2020, at Women's Hospital, University of Campinas, São Paulo, Brazil were considered. The ENG-implant or other contraceptive methods were offered prior to hospital discharge. The participants were split into two groups: (1) those who chose the ENG-implant and (2) those that refused the implant. Descriptive, bivariate, and multivariate analyses were performed. 151 women were included, with 76.2% selecting the ENG-implant. The average age was 19.5 years; 73.2% of pregnancies were unplanned, 32.5% already had a previous pregnancy, 74% were single, and 75.5% were not in full time education. Further, 70.5% had previously used contraceptives, with 89.1% unsatisfied with their previous method that opted for the ENG-implant (P = 0.07). Offering the ENG-implant to youths during the immediate postnatal period is evidence-based care, and contraceptive provision is an essential health promotion tool, even during a pandemic. Thinking quickly about public policies in times of crisis is important to guarantee sexual and reproductive rights.

Identifiants

pubmed: 33656758
doi: 10.1002/ijgo.13663
pmc: PMC9087758
doi:

Substances chimiques

Contraceptive Agents, Female 0
Drug Implants 0
etonogestrel 304GTH6RNH
Desogestrel 81K9V7M3A3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-112

Subventions

Organisme : São Paulo Research Foundation (FAPESP)
ID : 2018/20868-9

Informations de copyright

© 2021 International Federation of Gynecology and Obstetrics.

Références

Am J Obstet Gynecol. 2017 Jul;217(1):55.e1-55.e9
pubmed: 28257962
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
Contraception. 2019 Oct;100(4):258-263
pubmed: 31145885
Stud Fam Plann. 2015 Dec;46(4):355-67
pubmed: 26643487
Obstet Gynecol. 2012 Oct;120(4):983-8
pubmed: 22996129
Best Pract Res Clin Obstet Gynaecol. 2020 Jul;66:41-54
pubmed: 32217053
Women Health. 2020 Feb;60(2):179-196
pubmed: 31122167
Ethn Dis. 2020 Sep 24;30(4):525-532
pubmed: 32989352
Obstet Gynecol Clin North Am. 2020 Sep;47(3):463-475
pubmed: 32762931
Glob Health Sci Pract. 2017 Dec 28;5(4):547-570
pubmed: 29284694
Contraception. 2015 Dec;92(6):536-42
pubmed: 26209863
Rev Bras Ginecol Obstet. 2018 Aug;40(8):437-443
pubmed: 30142663
Contraception. 2008 Nov;78(5):409-17
pubmed: 18929739
Eur J Contracept Reprod Health Care. 2019 Dec;24(6):438-443
pubmed: 31566415
Rev Bras Ginecol Obstet. 2019 Oct;41(10):607-612
pubmed: 31658488
Contraception. 2017 Jun;95(6):564-570
pubmed: 28238839
Eur J Contracept Reprod Health Care. 2020 Aug;25(4):319-320
pubmed: 32436743
Am J Obstet Gynecol. 2019 Jul;221(1):43.e1-43.e11
pubmed: 30885772
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Int J Gynaecol Obstet. 2017 Feb;136(2):113-119
pubmed: 28099730
J Womens Health (Larchmt). 2020 Jun;29(6):815-818
pubmed: 31990605
Perspect Sex Reprod Health. 2014 Sep;46(3):171-5
pubmed: 24861029
Lancet Child Adolesc Health. 2018 Mar;2(3):223-228
pubmed: 30169257
J Pediatr Adolesc Gynecol. 2020 Oct;33(5):448-454
pubmed: 32621879
BJOG. 2014 Mar;121 Suppl 1:40-8
pubmed: 24641534
Am J Obstet Gynecol. 2021 Mar;224(3):282.e1-282.e17
pubmed: 32898503
Matern Child Health J. 2006 Nov;10(6):511-6
pubmed: 16807794

Auteurs

Mariane Massaini Barbieri (MM)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, SP, Brazil.

Thuany Bento Herculano (TB)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, SP, Brazil.

Amanda Dantas Silva (A)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, SP, Brazil.

Luis Bahamondes (L)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, SP, Brazil.

Cassia Raquel Teatin Juliato (CRT)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, SP, Brazil.

Fernanda Garanhani Surita (FG)

Department of Obstetrics and Gynecology, University of Campinas Faculty of Medical Sciences, Campinas, SP, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH